MHRA Cites Wockhardt Plant for GMP Noncompliance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

MHRA Cites Wockhardt Plant for GMP Noncompliance


The Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a statement of noncompliance against Wockhardt's site in Chikalthana, India and the company's contract manufacturer Nestor in the United Kingdom. The issuance of noncompliance follows manufacturing problems for Wockhardt earlier this year at its site in Waluj, India.

"We have issued a statement of noncompliance against Wockhardt’s site in Chikalthana, India and Wockhardt’s contract manufacturer Nestor Ltd. in the UK after recent inspections identified a number of manufacturing issues that breach good manufacturing practice (GMP) guidelines," said a MHRA spokesperson. 

“People should continue to take their medicines as usual because although the products have not been manufactured in line with GMP requirements, there is no evidence of a safety risk to patients," said the MHRA spokesperson. "We are working with the Department of Health to ensure that people have access to the medicines they need. Anyone who has questions should speak to their pharmacist or GP [general practitioner]," said the spokesperson.

In July 2013, MHRA issued a precautionary recall of 16 different prescription medicines made by Wockhardt at its Waluj site in India because MHRA identified manufacturing deficiencies during an inspection and noted that the medicines have not been manufactured to GMP standards. The recall was issued to pharmacies, dispensing clinics, and wholesalers, but not patients. The deficiencies identified by the MHRA during a routine inspection in March 2013 included a low risk of cross-contamination because of poor cleaning practices and defects in building fabric and ventilation systems at the site. There was also evidence of forged documents relating to staff training records that had been rewritten.

See related story, MHRA Recalls Medicines Made at Wockhardt's Waluj Site (July 2013)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here